Uroflowmetry is a viable surrogate for urethroscopy in evaluation of anatomical success following urethroplasty.


Journal

International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237

Informations de publication

Date de publication:
04 2023
Historique:
received: 03 08 2022
accepted: 15 12 2022
medline: 4 4 2023
pubmed: 29 12 2022
entrez: 28 12 2022
Statut: ppublish

Résumé

This study aimed to investigate the utility of uroflowmetry in predicting anatomical success following urethroplasty based on real-world clinical data. Data from 100 male patients who underwent urethroplasty for urethral strictures at our institute were analyzed. Postoperative anatomical success was determined as the passage of a 16.2 Fr flexible endoscope after approximately 4 months following the procedure. Sensitivity and specificity of the maximal flow rate (Q Anatomical success was observed in 67%. Voided volumes in the success and failure groups were equivalent: 252 ± 121 versus 242 ± 91 ml, respectively. In 18 cases, voided volumes were <150 ml. Parameters of uroflowmetry were all significantly higher in the anatomical success group when compared to those in the failure group: the mean value of Q This analysis presents statistically valid cutoffs by which uroflowmetry can be used as a viable surrogate of anatomical success following urethroplasty in clinical practice.

Identifiants

pubmed: 36575864
doi: 10.1111/iju.15137
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

390-394

Informations de copyright

© 2022 The Japanese Urological Association.

Références

Campos-Juanatey F, Osman NI, Greenwell T, Martins FE, Riechardt S, Waterloos M, et al. European Association of Urology guidelines on urethral stricture disease (part 2): diagnosis, perioperative management, and follow-up in males. Eur Urol. 2021;80:201-12.
DeLong J, Buckley J. Patient-reported outcomes combined with objective data to evaluate outcomes after urethral reconstruction. Urology. 2013;81:432-6.
Erickson BA, Elliott SP, Voelzke BB, Myers JB, Broghammer JA, Smith TG, et al. Multi-institutional 1-year bulbar urethroplasty outcomes using a standardized prospective cystoscopic follow-up protocol. Urology. 2014;84:213-6.
Erickson BA, Breyer BN, McAninch JW. The use of uroflowmetry to diagnose recurrent stricture after urethral reconstructive surgery. J Urol. 2010;184:1386-90.
Tam CA, Voelzke BB, Elliott SP, Myers JB, McClung C, Vanni AJ, et al. Critical analysis of the use of uroflowmetry for urethral stricture disease surveillance. Urology. 2016;91:197-202.
Tsang WC, Raman L, Wai Z, Guo H, Consigliere D, Chiong E. Validation of the TOTO Flowsky® uroflowmetry device. Eur Urol Suppl. 2017;16:e1959-60.
Fluss R, Faraggi D, Reiser B. Estimation of the Youden index and its associated cutoff point. Biom J. 2005;47:458-72.
Lambert E, Denys MA, Poelaert F, Everaert K, Lumen N. Validated uroflowmetry-based predictive model for the primary diagnosis of urethral stricture disease in men. Int J Urol. 2018;25:792-8.
Erickson BA, Breyer BN, McAninch JW. Changes in uroflowmetry maximum flow rates after urethral reconstructive surgery as a means to predict for stricture recurrence. J Urol. 2011;186:1934-7.
Amend GM, Nabavizadeh B, Hakam N, Voelzke BB, Smith TG III, Erickson BA, et al. Urethroscopic findings following urethroplasty predict the need for secondary intervention in the long term: a multi-institutional study from trauma and urologic reconstructive network of surgeons. J Urol. 2022;207:857-65.

Auteurs

Toeki Yanagi (T)

Department of Urology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.

Akihiro Kanematsu (A)

Department of Urology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.

Kimihiro Shimatani (K)

Department of Urology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.

Shingo Yamamoto (S)

Department of Urology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH